New advances in severe adverse drug reactions

Dermatologic Clinics

Volumn 19, Issue 4, 2001, Pages 697-709

  Revuz, Jean ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARBAMAZEPINE; CEPHALOSPORIN; CHLOROQUINE; CORTICOSTEROID; DOXYCYCLINE; GOLD SALT; HYDROXYCHLOROQUINE; HYPOCHLORITE SODIUM; IMIPENEM; ISONIAZID; MACROLIDE; MINOCYCLINE; NICORANDIL; NIFLUMIC ACID; NYSTATIN; PARACETAMOL; PENTOXIFYLLINE; PHENINDIONE; PHENOBARBITAL; PIROXICAM; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TERBINAFINE; VANCOMYCIN;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADVERSE DRUG REACTION; ATOPY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG METABOLISM; DRUG WITHDRAWAL; EPIDERMOLYSIS BULLOSA; ERYTHEMA MULTIFORME; HUMAN; MOUTH ULCER; NEUTROPHILIA; PRIORITY JOURNAL; PROGNOSIS; PUSTULOSIS; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VIRUS INFECTION;

EID: 0034765497     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70309-0     Document Type: Article

References (76)

1. The use of skin testing in the investigation of cutaneous adverse drug reaction
2. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis
3. A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme
4. Direct MCH-dependent presentation of the drug sulfamethoxazole to human αβ T cell clones
5. Pustuloses exanthématiques aïgues généralisées. A propos de 4 cas
6. Acute generalized exanthematous pustulosis
7. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug rash with eosinophilia and systemic symptoms-DRESS)
8. Aphtose buccale gé ante induite par le nicorandil
9. Analysis of the literature about drug-induced aphthous ulcers
10. A Guide to Drug Eruptions: Side Effects in Dermatology ed 7. Amsterdam
11. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with pneumocystis carinii pneumonia and AIDS
12. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole during treatment of AIDS-associated Pneumocystis carinii pneumonia
13. Drug rashes. What are the targets of cell-mediated cytotoxicity?
14. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome
15. Phenytoin-induced severe cutaneous drug reactions: Suspected interactions with corticosteroids and H2-blockers
16. Hypersensitivity syndrome due to 2 anticonvulsant drugs
17. Cutaneous T-cell recruitment in toxic epidermal necrolysis, further evidence of CD8+ lymphocyte involvement
18. Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome
19. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis
20. Adverse drug reactions: Definition, diagnosis, and management
21. Lack of significant treatment effect of plasma exchange in the treatment of drug induced toxic epidermal necrolysis?
22. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death?
23. Lyell's syndrome: Treatment by plasma exchange
24. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids
25. Toxic epidermal necrolysis, a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids
26. Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics
27. Epidemiology of drug allergy: Drug monitoring
28. High-dose trimethoprim-sulfamethoxazole therapy with corticosteroids in previously intolerant patients with AIDS-associated Pneumocystis carinii pneumonia
29. Thalidomide promotes the release of tumor necrosis factoralpha and lethality by lipopolysaccharide in mice
30. Plasmapheresis in severe drug-induced toxic epidermal necrolysis
31. Burn center care for patients with toxic epidermal necrolysis
32. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material
33. Diagnosis, classification and management of erythema multiforme and Stevens-Johnson syndrome
34. Pulmonary complications in toxic epidermal necrolysis: A prospective clinical study
35. Human herpesviruses 6 and 7. New roles yet to be discovered?
36. Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome
37. Generalized pustular drug rash
38. A case of toxic epidermal necrolysis treated with intravenous immunoglobin
39. Oral ulcers induced by nicorandil: Prevalence and clinicopathological aspects
40. Current concepts: Initial management of burns
41. Thahdomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
42. Macrophages and tumor necrosis factor in toxic epidermal necrolysis
43. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis
44. S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin
45. Acute neutrophilic dermatosis with myeloblastic infiltrate in a leukemia patient receiving all-trans-retinoic acid therapy
46. Measurement on involved surface area in patients with psoriasis
47. Toxic epidermal necrolysis, treatment with pentoxifyllin
48. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions
49. Toxic epidermal necrolysis: Clinical findings and prognosis factors
50. Adverse cutaneous reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia
51. Neutrophilic drug eruptions
52. Treatment of SJS and TEN
53. Acute generalized exanthematous pustulosis, analysis of 63 cases
54. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
55. Toxic epidermal necrolysis in patients receiving glucocorticosteroids
56. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus
57. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN)
58. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity
59. Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS
60. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
61. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk
62. Toxic pustuloderma. A new entity
63. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome
64. Management of nonstaphylococcal toxic epidermal necrolysis: Follow-up study of 16 case histories
65. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6
66. Inhibition of toxic epidermal necrolysis by blockade of CD 95 with human intravenous immunoglobulin
67. Immunopathology of toxic epidermal necrolysis
68. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
69. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: Case report and review of drug-induced Sweet's syndrome
70. A slow acylator genotype is a risk factor for sulphonamideinduced toxic epidermal necrolysis and Stevens-Johnson syndrome
71. Metabolic predisposition to cutaneous adverse drug reactions: Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants
72. Patchtesting in severe cutaneous adverse drug reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
73. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
74. Infiltration of cytotoxic T cells in drug induced cutaneous eruptions
75. Elevated serum levels of interleukins 5, 6 and 10 in a patient with drug-induced exanthem caused by systemic corticosterods
76. Cutaneous Drug Reactions